Spondyloarthritis & psoriatic arthritis
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
Authors' conclusion
More patients treated with deucravacitinib met each of the MDA components vs placebo, along with a higher rate of MDA response, after 16 weeks of treatment.
Study context
- Population
- Patients with PsA in a phase 2 trial
- Participants
- 203 patients
- Comparison
- Deucravacitinib 6 mg or 12 mg once daily vs placebo
- Primary endpoint
- Proportions of patients achieving MDA and each of the seven individual MDA components
- Follow-up
- Week 16
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Achievement of threshold criteria for each MDA component
- A greater percentage of patients treated with either dose of deucravacitinib vs placebo achieved the threshold criteria for meeting minimal disease activity (MDA) in each of the components
Further findings
Mean reduction from baseline in MDA components · over 16 weeks
- Numerically greater mean reduction from baseline in all MDA components with deucravacitinib vs placebo
Composite MDA at baseline
- None of the patients met the composite MDA criterion; components balanced across arms
Original publication
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial. Rheumatology (Oxford). Published 18 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →